Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.23) by 16.26 percent. This is a 35.63 percent increase over losses of $(1.60) per share from the same period last year.
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.23) by 16.26 percent. This is a 35.63 percent increase over losses of $(1.60) per share from the same period last year.
Comments